Cathay Biotech (SH:688065) Great Wall Securities·2025-08-27 08:07Investment Rating - The report maintains a "Buy" rating for the company, expecting a stock price increase of over 15% relative to the industry index in the next six months [5][19]. Core Viewpoints - The company's revenue and profit have shown significant year-on-year growth in the first half of 2025, driven primarily by the continued expansion of long-chain dicarboxylic acid products [2][11]. - The company is focusing on technological innovation and has made substantial progress in various R&D projects, which are expected to support future business expansion [4][8]. - The company is actively collaborating with partners to promote the application of bio-based polyamide and its composite materials, enhancing its market position [8][11]. Financial Performance Summary - For the first half of 2025, the company reported a revenue of 1.671 billion, a year-on-year increase of 15.68%, and a net profit attributable to shareholders of 309 million, up 24.74% year-on-year [1][2]. - The gross profit margin for the first half of 2025 was 33.85%, an increase of 2.63 percentage points compared to the same period in 2024 [2]. - The company’s operating cash flow decreased by 22.08% year-on-year, while the cash and cash equivalents balance increased by 87.48% year-on-year to 8.684 billion [3]. R&D and Innovation Summary - The company invested 123 million in R&D in the first half of 2025, representing 7.37% of its revenue, with significant advancements in green dicarboxylic acid and bio-based polyamide projects [4][8]. - The company has established partnerships to develop bio-based composite materials for various applications, including energy storage and automotive components [8][9]. Future Growth Prospects - The company is expected to achieve revenues of 3.537 billion, 4.704 billion, and 5.704 billion for the years 2025, 2026, and 2027, respectively, with corresponding net profits of 677 million, 817 million, and 1.012 billion [1][11]. - The ongoing construction of the Shanxi Synthetic Biology Industrial Park, with a total planned investment of 80 billion, is anticipated to enhance the company's production capacity and market leadership [9].